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Executive summary 
 
On 18 April 2007, The Cancer Council Australia convened a national roundtable 
discussion on human papillomavirus (HPV) immunisation and its impact on the National 
Cervical Screening Program. The aim was to bring leaders in immunisation and screening 
together to share their expertise, examine the latest evidence and develop 
recommendations for policy makers. The Australian Government (Commonwealth 
Department of Health and Ageing) co-sponsored the event. 
 
The roundtable was convened in response to the emergence of a vaccine that prevents 
two strains of HPV that cause approximately 70% of cervical cancer. While HPV 
vaccination has the potential to significantly reduce the impact of cervical cancer, its 
introduction in Australia must be managed in a way that ensures Australia’s successful 
cervical cancer screening program continues to protect women who, for reasons 
documented in this report, would not benefit from the vaccine. 
 
The event gathered together the nation’s leaders in cervical cancer policy and 
implementation, with the key objectives to: identify what information is currently available 
for health professionals and the community about the HPV vaccine; lead discussion 
around the impact of HPV vaccination on the National Cervical Screening Program; and 
generate outcomes and recommendations that can help inform policy and practice. 
 
A key component of the roundtable was a workshop facilitated by Professor Terry Nolan, 
Head of School, School of Population Health, University of Melbourne, which identified: 
potential barriers to the successful rollout of the HPV vaccination program; potential 
barriers to ensuring the National Cervical Screening Program delivers optimal results 
following the introduction of HPV immunisation; and research questions that need to be 
addressed in the short and long term. The workshop rated the significance of key 
interventions under each of these headings, as documented in this report.  
 
The roundtable also featured formal presentations from experts in a range of fields related 
to cervical cancer control, which are summarised in Attachment 1.  
 
Following lengthy discussion, roundtable participants agreed on five principles around 
which a set of more detailed recommendations, and agencies with remit to explore them, 
are documented: 
1. Review the National Cervical Screening Program; 
2. ‘Central’ overseeing to monitor the HPV vaccine’s impact on the National Cervical 
Screening Program; 
3. Develop an Indigenous ‘package’ for screening and vaccination; 
4. Undertake post-implementation evaluation of the National HPV Vaccination 
Program; and 
5. Address information systems issues. 
 
This report lists these recommendations and summarises the discussion and presentations 
from the roundtable. Publication was deferred to enable additional expert input and to 
coincide with the subsequent development of the HPV immunisation chapter of The 
Cancer Council Australia’s National Cancer Prevention Policy. 
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Overview 
 
After more than three decades of opportunistic screening for cervical cancer in Australia, 
the Australian Federal Government, in partnership with the states and territories, 
introduced the National Cervical Screening Program in 1991. 
 
Between 1991 and 2002, the incidence rate of cervical cancer among women aged 20 to 
69 almost halved.1 Between 1991 and 2004, the cervical cancer mortality rate in Australia 
declined by more than 50%2 and is now among the lowest in the world.3 These declines in 
cervical cancer incidence and mortality can, in part, be attributed to the success of the 
National Cervical Screening Program. (In 2003, there were 725 new cases of cervical 
cancer in Australia and 239 deaths, which equated to 1.7% of total cancer incidence and 
0.6% of total cancer mortality.4) 
 
The National Health and Medical Research Council last reviewed guidelines for the 
National Cervical Screening Program in 2006. Australia’s current screening policy 
recommends that all sexually active women aged 18-69 have a Pap test every two years. 
 
In 1991, a research team based in the University of Queensland had begun developing a 
vaccine for HPV, which is identified in 99.7% of cervical cancer specimens.5 Clinical trials 
showed the vaccine to be 100% effective in preventing HPV types 16 and 18, responsible 
for up to 70% of cervical cancers.6 
 
In July 2006, the Therapeutic Goods Administration (TGA) approved Australia’s first HPV 
vaccine, Gardasil, for use in girls and women aged 9 - 26 and boys aged 9-15. A second 
vaccine, Cervarix, was being assessed for TGA approval for use in females, reportedly up 
to the age of 45, at the time of the national HPV roundtable.  
 
The Australian Government recently included Gardasil on the National Immunisation 
Program. Ongoing from April 2007, Gardasil is available to girls aged 12-13 (first year of 
secondary school). Additionally, for a two-year catch-up period the vaccine is available for 
girls and women aged 13 - 26.  
 
Subsequent to the HPV immunisation roundtable, in May the TGA granted Cervarix its first 
license in a major market for the prevention of cervical cancer and precancerous lesions 
caused by HPV types 16 and 18 for use in females ages 10-45 years. 
 
Rationale for convening roundtable 
 
The Cancer Council Australia welcomed the development of HPV vaccination as a major 
step forward in reducing cervical cancer incidence and mortality, both globally and in 
Australia. In a media statement in June 2006, the Cancer Council stated that TGA 
approval of Gardasil was “an exciting prospect”, particularly for future generations, while 
urging women who had been sexually active to continue participating in the cervical 
screening program. This position reflects the complexity of HPV immunisation in a country 
like Australia that has a successful cervical cancer screening program; this complexity 
motivated The Cancer Council Australia to convene the HPV immunisation roundtable. 
 
Evidence shows that the vaccine is highly effective at preventing HPV in women who have 
not been exposed to the virus through sexual activity. It has therefore been recommended 
by a group of international experts that the vaccine be administered prior to 
commencement of sexual activity. It is further recommended that vaccinated women have 
regular Pap tests, because the vaccine does not protect against all types of HPV that 
cause cervical cancer.6 
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While the vaccine has been added to the National Immunisation Program for girls and 
women aged 12-26, screening will need to continue for many decades to come. In the 
meantime, the vaccine’s impact on the screening program may be felt relatively quickly. 
 
The Cancer Council Australia hosted the HPV roundtable in order to explore these 
complexities and make recommendations for Australian policy makers on the basis of 
latest evidence, expert opinion and stakeholder involvement.  
 
Objectives 
 
The key objectives of the HPV roundtable were to: 
 
• Identify what information is currently available for health professionals and the 
community about the HPV vaccine; 
 
• Lead discussion around the impact of HPV vaccination on the National Cervical 
Screening Program; and 
 
• Generate outcomes and recommendations that can help inform policy and practice. 
 
Program 
 
Presentations 
 
The following presentations were delivered at the roundtable (see appendix 1 for 
summaries of individual presentation): 
 
Prof Ian Frazer, Director, Centre for 
Immunology and Cancer Research, 
University of Queensland 
HPV vaccination: an Australian perspective 
An overview of future HPV vaccine 
developments 
Dr Marion Saville, Director, Victorian 
Cytology Service 
Impact of HPV vaccination on the National 
Cervical Screening Program 
Assoc Prof Dorota Gertig, Director, 
Victorian Cervical Cytology Service 
A review of evidence for primary screening with 
HPV testing 
Dr Karen Canfell, Research Fellow, 
The Cancer Council NSW 
Modelling HPV vaccination and cervical 
screening in Australia 
Dr Sophie Couzos, Public Health 
Officer, National Aboriginal Community 
Controlled Health Organisation 
A focus on Aboriginal women for cervical cancer 
prevention 
Andriana Koukari, Assistant Secretary, 
Population Health Programs Branch, 
Department of Health and Ageing 
A review of materials available for health 
professionals and the community about the 
vaccine 
An Australian Government perspective on the 
rollout of the HPV immunisation program and its 
impact on the National Cervical Screening 
Program 
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Discussion: barriers and research questions 
 
A key component of the roundtable was a workshop facilitated by Professor Terry Nolan, 
Head of School, School of Population Health, University of Melbourne, which identified: 
 
1. Potential barriers to the successful rollout of the HPV vaccination program; 
 
2. Potential barriers to ensuring the National Cervical Screening Program delivers 
optimal results following the introduction of HPV immunisation; and  
 
3. Research questions that need to be addressed in the short and long term. 
 
All potential barriers and research questions documented here were considered important, 
with a ranking system ranging from + for ‘significant’ to +++ for ‘most significant’. The 
workshop also recommended strategies for overcoming the barriers.  
 
1. Potential barriers to the successful rollout of the HPV vaccination program 
 
Ranking Barriers  Strategies 
+++ Recognising the higher incidence and 
poorer outcomes in the ATSI 
community, a focus on equity in HPV 
vaccination service delivery is a high 
priority  
Address in policy and provide 
appropriate funding 
+++ Varying logistical needs – the program 
needs enhanced infrastructure, 
information systems and strong links 
with GPs and other health professionals 
Develop national registry to 
address infrastructure and 
information system needs 
 
+++ Coordination across professional 
boundaries is required 
Identify stakeholders and changes 
needed to achieve 
++ Communicating information about HPV 
and the vaccine – recognising that the 
way in which vaccination is presented to 
health professionals, parents, women 
and adolescents could impact vaccine 
uptake 
Develop communications strategy 
to address issues of adolescent 
and parental consent  
++ Introduction of GSK vaccine (Cervarix) 
could create confusion for health 
professionals and women 
Develop communications strategy 
to address this issue 
+ Reported vaccine “failures” leading to a 
loss of confidence in the vaccination 
program by providers and women  
Develop communications strategy 
to provide explanations 
+ Arguments put by anti-immunisation 
lobbyists have the potential to confuse 
or dissuade participation in immunisation
Develop communications strategy 
to provide responses  
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2. Potential barriers to ensuring the National Cervical Screening Program delivers 
optimal results following the introduction of HPV immunisation 
 
Ranking Barriers  Strategies 
+++ Sustainability (or non-sustainability) of 
the existing National Cervical 
Screening Program 
Fund research including modelling 
studies 
+++ The potential for reduced uptake of 
screening after vaccination – 
vaccinated girls may believe that they 
do not need to participate in the 
screening program, and; with an 
increased awareness of the role of 
HPV, women may (inaccurately) 
believe that they no longer need Pap 
tests. Confusion about screening has 
the potential to increase when the 
second vaccine (Cervarix) becomes 
available 
Develop communications strategy to 
address lack of knowledge/ 
confusion about screening, 
especially in under-screened 
women  
+++ Resistance to changes to the National 
Cervical Screening Program by health 
professionals 
Engage key health professionals 
and opinion leaders to lead change 
+++ Appropriate time to plan Commence planning  
+ Need to understand/map the success 
of the National Cervical Screening 
Program, with a particular focus on 
recruitment 
Investigate programs (not 
exclusively screening) that are 
targeting the ATSI community well 
+ Commercialisation of new 
technologies – can create confusion 
for women and health professionals 
Develop communications strategy to 
address 
 
3. Research questions that need to be addressed in the short and long term 
 
Ranking Research questions/topic areas  
+++ Compile the evidence on barriers to screening and the various experiences in 
different states 
How acceptable are different screening tests (ie, is self-sampling/or HPV DNA 
testing really more acceptable/culturally appropriate in underscreened 
communities)?  
Innovative strategies are required to ensure equity of access to the National 
Cervical Screening Program and National HPV Vaccination Program. 
+++ Monitoring and evaluation of the National HPV Vaccination Program. Monitor 
full range of impacts (and set targets) including, effect on the screening 
program (rates of cervical cancer, incidence of LSIL and HSIL); population 
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impact on genital warts; service delivery and uptake in ATSI community; 
before-and-after prevalence studies 
+++ What is the most effective way of screening for cervical cancer in a 
vaccinated population? 
+++ Genotype replacement over time 
+++ Duration of lifetime protection following natural infection, especially in older 
women 
++ Evidence to support communication and implementation strategies 
++ The feasibility of packaging HPV vaccination as part of a general adolescent 
health check - general need for investigation into how HPV vaccination can 
be embedded into more general aspects of adolescent healthcare.  
++ An understanding of the natural history of HPV infection in older women – 
potential existence of second peak of prevalence of infection in older women 
in Australia.  
++ Evidence for two versus three doses of the vaccine 
+ Duration of vaccine efficacy and booster requirement 
+ Epidemiology of HPV and vaccination in boys 
+ Infant vaccination research – leading to possibility of earlier delivery 
+ Knowledge about the acceptability of the HPV vaccine for NESB communities 
 
 
Recommendations 
 
Participants at the national HPV immunisation roundtable agreed on a set of 
recommendations to be adopted by national policy makers, built around five key areas of 
activity: 
 
 
1. Review the National Cervical Screening Program; 
2. ‘Central’ overseeing to monitor the HPV vaccine’s impact on the National Cervical 
Screening Program; 
3. Develop an Indigenous ‘package’ for screening and vaccination; 
4. Undertake post-implementation evaluation of the National HPV Vaccination 
Program; and 
5. Address information systems issues. 
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The group proposed a range of specific initiatives and nominated organisations to take 
action, as follows: 
 
1. Review the National Cervical Screening Program 
 
It should be recognised that the National Cervical Screening Program is essentially a 
program to prevent cervical cancer. A formal review of the National Cervical Screening 
Program is required – developing a framework and timeline for this is a priority.  
 
The review should recognise and address the following: 
 
• Screening interval and age of screening – reducing cancer through primary 
prevention will make the existing screening program much less cost-effective. 
Screening will still be required, albeit at reduced intervals for the vaccinated cohort. 
Modelling of screening pathways is required. 
 
• Capacity – there will be a reduction in the number of lesions as the vaccinated 
cohort enters the screening program. Fewer abnormalities seen by scientists may 
lead to reduced expertise. This has implications for laboratory measures, which will 
need to be adjusted as a consequence. Additionally, recruitment issues will 
become apparent as fewer scientists enter the field of cytology as a result of 
decreasing demand. 
 
• Primary screening – need formal review of primary screening with HPV testing. 
 
• Equity – the review should include an equity impact assessment to determine the 
screening program’s impact on reaching unscreened and under-screened women, 
and how this could be improved. 
  
Actions for implementing this recommendation should be the responsibility of the 
Screening Subcommittee of the Australian Population Health Development Principal 
Committee (APHDPC), which itself is a function of the Australian Health Ministers’ 
Advisory Committee. The APHDPC’s Screening Subcommittee should establish a working 
group to implement these measures in order to incorporate additional expertise as 
required. 
 
2. ‘Central’ overseeing to monitor the HPV vaccine’s impact on the National 
Cervical Screening Program  
 
It is important for systems and processes to be developed that monitor the HPV vaccine’s 
impact on the National Cervical Screening Program. These should encompass: 
 
• Data collection – identify the data required and ensure that it is captured in data 
collection processes; 
 
• Monitoring – develop a process to monitor data collected; and  
 
• Evaluation – analysis of data to measure any impact the vaccine may have on the 
National Cervical Screening Program. 
 
Responsibility for this recommendation should rest with the APHDPC’s Screening 
Subcommittee, again by acquiring additional specific expertise as required. 
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3. Develop an Indigenous ‘package’ for screening and vaccination 
 
Aboriginal women are up to five times more likely to die from cervical cancer than non-
Aboriginal Australian women, largely because they are less likely to participate as 
recommended in the National Cervical Screening Program.7 In order to reduce this 
inequity in cervical cancer outcomes, targeted efforts are required to expedite HPV 
immunisation of Aboriginal girls and women.  
 
Recommended guiding principles for such targeted efforts, and ways to apply them, are:  
 
• Access – Aboriginal people are more likely to be vaccinated attending an Aboriginal 
Community Controlled Health Organisation (ACCHO) than via private medical 
practice. ACCHOs and Aboriginal health workers should therefore be involved in 
the development of communication initiatives to promote the vaccine and measures 
to overcome structural/logistical barriers to the vaccine’s delivery. Additionally, any 
immunisation incentive programs should be designed to support ACCHOs; 
 
• Identification – the National HPV Register and state-based cytology registers 
should include Aboriginal identifiers. For cytology registers to collect this data, the 
National Pathology Accreditation Advisory Council (NPAAC) standards could be 
amended to include recording of Aboriginal status as a standard. This would then 
need to be adhered to by all pathology laboratories reporting Pap test results; and 
 
• Uptake – establish targets for the ongoing vaccination program and two catch-up 
programs. Determine what percentage of uptake in the Aboriginal community is 
considered successful? As Aboriginal girls are more likely to leave school at an 
earlier age and are more transient, targeted efforts to reach women in the catch-up 
programs is also required; relying on the school-based program alone is 
insufficient. 
 
Responsibility for this recommendation rests with the Department of Health and Ageing 
Population Health Programs Branch, Targeted Prevention and Programs Branch and the 
Screening Subcommittee of APHDPC.  
 
4.  Undertake post-implementation evaluation of the National HPV Immunisation 
Program  
 
An evaluation framework is required for the National HPV Immunisation Program. This 
should include targets for measurement, and cover important components such as: 
 
• Equity – is the program reaching girls and women most at risk of cervical cancer 
(Aboriginal women, women from socially and economically disadvantaged 
background, women of culturally and linguistically diverse background etc.)? 
 
• Participation – establish targets for the ongoing program and two catch-up 
programs. What percentage of participation is considered successful? 
 
• Impact – direct effect on the number of cervical lesions, cervical cancer incidence 
and mortality, and screening participation rates (are vaccinated women less likely 
to participate in Pap testing?). 
 
The Department of Health and Ageing’s Population Health Programs Branch and Targeted 
Prevention Programs Branch would take responsibility for these measures. 
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5. Address information systems issues 
 
The way in which medical data is recorded and managed differs between states and 
territories. It is important that data linkages across states/territories and within sectors are 
streamlined and improved. Communicating across sectors will also need to improve. 
 
Responsibility for this recommendation rests with the Department of Health and Ageing 
Population Health Programs Branch and Targeted Prevention and Programs Branch. 
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Appendix 1 - presentations 
 
The six formal presentations delivered at the roundtable are summarised as follows. 
 
________________________________________________________________________ 
 
HPV vaccination: an Australian perspective 
An overview of future HPV vaccine developments 
 
- Professor Ian Frazer∗, Director, Centre for Immunology and Cancer Research, University 
of Queensland 
 
 
 
Key points 
 
• Infections, including HPV, hepatitis B & C, H. 
Pylorii and Epstein Barr cause more than 23% 
of cancers, of which more than a fifth are 
causes by HPV 
 
• HPV is the second most common cause of 
cancer in women worldwide 
 
• There’s an average 15-year delay between 
HPV infection and cancer 
 
• Immunity has been shown to control many HPV infections 
 
• Role of adaptive (specific) immunity is uncertain 
 
• Innate (non-specific) immunity is important 
 
• Protection post-immunisation is by serum antibody to virus-like particle 
conformation 
 
• Prophylactic HPV vaccines are:  
o conventional vaccines  
o made using rDNA technology (HPV can’t be grown in tissue culture) 
o based on technology for production of L1 virus like particles 
o produced by expressing the papillomavirus capsid protein in cells using 
gene technology 
o resemble the virus physically and immunologically 
 
• Using the same technology, there are two vaccines – Gardasil, which immunises 
against HPV strains 6,11,16,18, and Cervarix, which protects against strains 16 
and 18 
 
• Laboratory work on the vaccine began in 1980, with licensing of the first product in 
2006; the first clinical trials of the virus-like particle was 1995 
                                                 
∗ Professor Frazer disclosed that he and the University of Queensland, which developed HPV immunisation 
under his leadership, may gain financially from the commercial sale of the vaccine. 
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• Clinical trials showed the vaccine to be 100% efficacious against HPV strains 
6,11,16,18 
 
• Evidence shows best antibody response is in prepubescent youths 
 
• The vaccine is not therapeutic – it has no effect on pre-existing HPV infection 
 
• The vaccine is most efficacious before the risk of HPV infection is high (it is not 
possible to screen for a past infection) 
 
• Clinical trials showed no vaccine side effects; identical ratio (3.6%) of pregnant 
women in both the vaccine and the placebo group reported adverse congenital 
abnormalities 
 
• 2 million doses administered over six months, with 750 possibly associated events 
reported - mostly fainting after vaccination (one broken nose). Three related cases 
of Guillain Barre syndrome were reported 
 
• Next steps include longer term research to demonstrate duration of vaccine 
protection, studies of vaccine efficacy in men and the development of broader 
spectrum vaccines 
 
• HPV vaccine licensed for use in more than 50 countries, with government 
immunisation programs in Australia, Germany and Italy 
 
Conclusion 
 
• If administered before sexual activity, HPV immunisation will prevent: up to 70% of 
cervical cancer in an unscreened population; the majority of abnormal Pap smears 
in screened populations; and more than 90% of genital warts (no data for males 
yet) 
 
• HPV immunisation should not be seen as a replacement for cervical cancer 
screening 
  
• HPV vaccines provide no therapeutic benefit for existing infection 
 
________________________________________________________________________ 
 
Impact of HPV vaccination on the 
National Cervical Screening Program 
 
 
- Dr Marion Saville, Director, Victorian Cytology 
Service 
 
Key points 
 
There are three main impacts of cervical cancer 
immunisation in Australia: 1) confusion about 
the need to continue screening; 2) reduction in 
the numbers of abnormalities detected; and 3) 
reduction in the number of cancers 
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Confusion about the need to continue screening 
 
• Any change to screening recommendations will not affect women already being 
screened, so our existing programme will need to continue in some form until the 
youngest of these women reaches the age of stopping screening, presently 69 
years 
 
• The vaccine only protects against HPV 16- and 18-related cancers, so some form 
of screening will still be required by the vaccinated cohort  
 
• Workforce implications in cytology – anecdotal reports of student reluctance to 
select cytology as a major subject, potentially leading to decline in capacity to 
screen before commensurate decline in demand 
 
Reduction in the number of abnormalities detected in Pap tests 
 
• When the vaccinated cohort enters the screening program, low-grade squamous 
intraepithelial lesions are expected to decline by around 20%, high-grade SIL by 
40% for those vaccinated against HPV 16/18 and 50% for those vaccinated against 
6/11/16/18 
 
• Reduced LSIL and HSIL may lead to a reduction in the positive predictive value 
(PPV) of diagnoses and reduced scientific expertise in treating such abnormalities 
 
• The National Pathology Accreditation Advisory Committee will need to review the 
screening program’s laboratory performance standards in view of the decline in 
abnormalities 
 
• Image-assisted liquid-based cytology may have two strategic advantages not 
captured by cost-effectiveness analyses: 
 
o delivering the increased productivity that may be needed if our capacity to 
report cytology falls below demand in the next five to 10 years 
 
o increased productivity could also compensate for the reduced prevalence of 
abnormalities, maintaining the absolute number of abnormalities seen by 
scientists 
 
Reduction in the number of cancers 
 
• Australian-specific data suggests that HPV 16/18 may account for closer to 80% of 
cervical cancers – 10% higher than global average 
 
• It will take decades for immunisation to reduce cervical cancer incidence in 
Australia 
 
• Reduction in cervical cancer burden through primary prevention will eventually 
make the screening program much less cost-effective. 
 
Cervical screening in the era of HPV vaccination – key questions 
 
• Do we have different programmes for screened and unscreened women? 
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• Will practitioners contact an immunisation register on a woman-by-woman basis 
before conducting a Pap test? 
 
• Will practitioners rely on women’s recall? 
 
• Do we screen all women less intensively? 
 
Equity issues 
 
• Immunisation could benefit some population groups over others 
 
• Women in apparently vaccinated cohorts may still develop cervical cancer 
because: they were not vaccinated; missed some doses; the vaccine did not work 
 
HPV testing as part of cervical cancer screening – barriers 
 
• HPV testing is more expensive than conventional cytology 
 
• HPV screening would depend on commercial interests 
 
• There are complex public health education issues 
 
• The IARC Cervix Cancer Screening Meeting in April 2004 concluded: 
 
o There is sufficient evidence that: screening by conventional cytology has 
reduced cervical cancer incidence and mortality rates 
 
o screening by liquid-based or automated cytology can reduce cervical cancer 
incidence and mortality rates 
 
o testing for human papillomavirus infection as the primary screening modality 
can reduce cervical cancer incidence and mortality rates 
 
Conclusion - how will cervical screening work in the HPV immunisation era? 
 
• Screening must be reformulated to operate in conjunction with immunisation 
 
• We must recognise there are two prevention strategies: one new and the other in 
transition 
 
• Decisions about screening the vaccinated cohort will need to be made without the 
benefit of empirical data 
 
• Modelling will be needed to assist decision making 
 
• Detailed post-vaccination surveillance is essential to providing evidence 
 
HPV Register 
 
• A national HPV vaccination register is being developed to collect information about 
the HPV immunisation program 
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• The immunisation program’s impact on cervical abnormality and cancer rates must 
be evaluated and matched with Pap test registers 
 
Next steps 
 
• Formal review of evidence on cervical cancer screening in the immunisation era 
 
• Model proposed new screening pathways 
 
• Implement modified screening for immunised age cohort 
 
• Assess the outcomes through post-vaccination surveillance, using immunisation 
and Pap test registers. 
 
________________________________________________________________________ 
 
 
A review of evidence for primary screening with HPV testing 
 
- Associate Professor Dorota Gertig, Director, Victorian Cervical 
Cytology Service 
 
Key points about HPV testing 
 
• Test is for high-risk HPV DNA from cervical specimens:  
o i) Hybrid capture II (13 high-risk and five low-risk 
subtypes) of HPV 
o ii) Polymerase chain reaction 
 
• Test does not refer to HPV serology, due to low 
sensitivity (<50%) 
 
• NHMRC guidelines released in 2006 recommend “test 
for cure” following treatment of a histologically proven 
high-grade cervical abnormality  
 
• Under these circumstances, Medicare rebate applies 
 
• Insufficient evidence of cost-effectiveness for use following LSIL. 
 
Case for HPV testing in cervical screening 
 
• Higher sensitivity than cytology 
 
• More “upstream” in carcinogenic process meaning there is potential for longer 
safety margin for screening intervals 
 
• Can be automated, centralised, quality-controlled for high specimen throughput 
 
• High-volume testing may be more cost-effective  
 
• A more intuitive choice for screening vaccinated women. 
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HPV as a primary screening test 
 
• HPV testing has a higher sensitivity and negative predictive value for cervical 
abnormalities but the trade-off is lower specificity and positive predictive value than 
cytology 
 
• Low specificity means more false positives and consequently greater number of 
unnecessary investigations especially colposcopy 
 
Study results: HPV testing v. cytology in population-based screening 
 
• Sensitivity for HPV testing substantially higher than for Pap testing, ranging from 
around 75% to 95-97%. 
 
• Pap testing had higher specificity than HPV testing which is particularly important in 
the context of population screening, because as the specificity goes down the 
false-positive rate goes up resulting in a higher number of unnecessary 
investigations and a more costly program.   
 
• Methodological limitations 
o all studies were based on cross-sectional design with double testing of all 
women 
o single HPV test compared with single Pap test  
o Outcome >=CIN2, but much of CIN2 regresses 
 
How can specificity be increased? 
 
• Cytology triage, i.e. conducting Pap tests on women who are found to be HPV 
positive  
 
• Role of HPV genotyping 
 
• Other novel markers of persistence:  
o viral load analysis  
o High-risk HPV mRNA analysis 
o p16 
o Microarray analyses. 
 
• An important research question is, What factors increase the risk of persistent 
infection or progression to cancer? 
 
• Specificity of HPV testing by age 
o Koliopoulos (2007): suggested similar specificity for women over 30 years  
o Cuzick (2006): specificity 7% higher in women aged 35 years and older 
compared to younger women 
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Psychological consequences of HPV testing 
 
• Low awareness of link between HPV and cancer, though this is increasing with 
publicity around the vaccine 
 
• Information about HPV tests can result in anxiety, concern about health and 
relationships 
 
• More health education is necessary 
 
Randomised controlled trials of HPV as a primary screening test 
 
• Seven ongoing RCTs of HPV as a primary screening test 
 
• Involve collection of samples for HPV and Pap test, randomised to reveal or 
conceal the HPV result 
 
• Main postulated outcome is a reduction in cumulative incidence of CIN3, three to 
five years after screening among baseline HPV negative women compared to 
baseline cytology negative women. 
 
General methodological issues 
 
• Most trials based within population-based screening programs 
 
• Target age groups and screening intervals differ 
 
• Management of HPV positive women, comparing either immediate colposcopy to a 
repeat test in six to 12 months which may impact on the sensitivity  
 
• Outcome >=CIN2 or >=CIN3 
 
• Issues around verification bias. 
 
Issues in adopting HPV testing in the cervical screening program  
 
• Changes to existing screening programs will be costly and require extensive 
changes in workforce 
 
• At present, HPV testing is more expensive  than cervical cytology 
 
• Health education issues 
 
• Possible adverse psychological consequences 
 
• Characteristics of Pap tests will differ post-vaccination. 
 
Where to next? 
 
• Proper evaluation of proposed changes to existing screening program 
 
• Await longitudinal data from ongoing RCTs (2007-08), however none of the studies 
are being conducted in the context of the national vaccination program 
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• Further research on triage of HPV positive women  
 
• Further research on risk factors for persistence 
 
• Role of modeling v. trial results. 
 
________________________________________________________________________ 
 
Modelling HPV vaccination and cervical cancer screening in Australia 
 
- Dr Karen Canfell, Cancer Epidemiology Research Unit, The Cancer Council NSW 
 
Note that Dr Canfell’s presentation was largely graphic and diagramatic in nature and could not be 
fully reproduced in this text-based summary. Dr Canfell provided an overview of a project modelling 
HPV vaccination and cervical cancer screening in Australia, the key points of which follow. 
 
The overall aims of the modelling project are to perform epidemiologic and health 
economic evaluations of potential changes to cervical screening in the context of HPV 
vaccination. Some of the outcomes from the project include: (1) Effectiveness - cancer 
incidence and mortality, life years saved; (2) Health resources utilisation – number of 
smears, colposcopies and treatments by age and over time; and (3) Costs – discounted 
lifetime costs, and annual costs of screening and vaccination. 
 
The approach involves a group of interlinked models – including a model of sexual 
behaviour and HPV transmission in Australia, a model of the natural history of CIN, a 
model of invasive cancer survival, and a model of screening, diagnosis and treatment. The 
dynamic model of HPV transmission was adapted from a model originally developed for 
Finland. It was parameterised for Australia using local data on the age of sexual debut, 
rates of partner change and hysterectomy, fertility and mortality rates. The model of 
screening, diagnosis and treatment was developed as a flexible platform and makes use of 
registry data to ensure that compliance with recommended re-screening and follow-up 
intervals are taken into account in the evaluations. 
 
The validation and initial application of the models were described and the results 
discussed. The HPV transmission model was used to estimate the impact of the current 
vaccination program on HPV incidence in Australia, and was also used to estimate the 
impact of vaccination of additional groups including males and older women. An initial 
application of the screening model - to perform an economic evaluation of proposed 
changes to cervical screening in New Zealand - was also described. 
 
Future work will focus upon evaluating the role of primary HPV testing in the context of 
HPV vaccination. 
 
________________________________________________________________________ 
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A focus on Aboriginal women for cervical cancer prevention 
 
- Dr Sophie Couzos, Public Health Officer, National 
Aboriginal Community Controlled Health Organisation 
 
Aboriginal Community Controlled Health Services  
 
• Over 130 services deliver comprehensive 
primary health care 
 
• Over 1.4 million episodes of care (2003-04) 
recorded by ACCHSs to Aboriginal and Torres 
Strait Islander peoples (vastly greater than 
private GP contacts (BEACH data) 
 
• 70% employees are Aboriginal 
 
• Significant source of training for all health 
professionals (e.g. KAMSC has provided training 
to over 600 Aboriginal Health Workers since its 
establishment) 
 
• Deliver more expansive programs and clinic services than general practice:  
 
• Provide clinical and preventive services 
 
• Advocacy and policy development 
 
• Support services. 
 
Cervical cancer 
 
• The most common cause of cancer death among Aboriginal women 
 
• Overall age standardised mortality rate is ~5 times greater than that of non-
Aboriginal women (in NT= 9 times higher) 
 
• Higher risk for Aboriginal women in rural and remote areas than those in 
metropolitan areas (probably reflects poor access to screening services) 
 
• Aboriginal women are younger: mean age of death= 53 years 
 
• Incidence ICC (AS): 11.4/100,000 Aboriginal cf 2.5/100,000 (Qld, WA, NT,SA, 
1998-2001) (also higher in NSW). 
 
Cervical screening coverage 
 
• Overall for all Australian women: 62-68% participation rates (PHOFA reports), but 
cervical screening participation rates not required to be reported/collected for 
Aboriginal women under the PHOFAs 
 
• Cross sectional survey: biennial participation rate for Aboriginal women in rural and 
remote areas was 41% (Qld), 30% lower than the rest of Queensland. 
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• In NT, 42% coverage (2003-04) 
 
• Pap smear participation rates overall are lower for Aboriginal women  
 
Human papilloma virus 
 
• Limited data, but rates of HPV infection for Aboriginal women appear about the 
same as for non-Indigenous population: 42% (NT), suggesting that high cancer 
rates are due to poor access to primary health care 
 
• There is limited data on the prevalence of different HPV types among populations 
of Aboriginal women. The prevalence of HPV and serotypes among Aboriginal 
women is being examined as in the WHINURS study (Women's HPV prevalence 
Indigenous Non-indigenous Urban Rural Study) that will help to inform future 
immunisation strategies 
  
• Pap smear is the main test for detection of cervical HPV infection. 
 
Poor primary health care access 
 
• Access to primary health care services can be ascertained by proportionate 
expenditure 
 
• Non-hospital spending: 
o MBS 34% of that for other Australians (per person) (including S100) 
o PBS 30% 
o Dental 24% 
 
• Primary health care spending from federal and state sources for Aboriginal people 
is only 1.2 times that for non-Aboriginal peoples (2001-02), when it should be at 
least three times higher. 
 
Immunisation coverage in general 
 
• Vaccine coverage for pre-school children: suboptimal (9-17% lower for Aboriginal 
children aged 2-6 years)* 
 
• Vaccine coverage for adults: not optimal and not directly comparable between 
populations. Influenza coverage for over 50 years of age 51% for Aboriginal and 
47% for non-Aboriginal. Aboriginal people are a specific target group – whereas the 
over 65 year old population is targeted for non-Aboriginal people 
 
• Aboriginal and Torres Strait Islander people are more likely to be vaccinated if 
attending ACCHSs than if attending private general practice 
 
• HPV vaccination through GPs must target ACCHSs. 
 
Enhancing Pap screening coverage 
 
• 84% of ACCHSs deliver women’s health programs (SAR 2000-01) 
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• 79% of ACCHSs provide Pap smears (not all ACCHSs are large enough to employ 
GPs) 
 
• Plus additional specific Pap programs 
 
• Context is important:  
o an accessible and appropriate environment (gender and culture)  
o choice of provider eg. many Pap smears are taken by Aboriginal Health 
Workers (AHWs) 
o holistic: women’s health is seen as part of overall wellbeing and is linked to 
the health of their families. 
 
STI control in general 
 
• Up to 70% of ACCHSs provide routine STI screening (as part of preventive health 
checks), treatment and contact tracing 
 
• Pap smears are part of that health check 
 
• Condoms may have a role in preventing HPV transmission (study findings are 
conflicting) 
 
• ACCHSs promote risk reduction and health seeking behaviour in innovative ways 
eg. “condom trees”. 
 
National Cervical Screening Program 
 
• Cervical cytology registers across Australia are not required to record Aboriginality 
(WA is taking some steps) 
 
• Funding agreements with the states don’t require reporting on Pap coverage for 
Aboriginal women 
 
• It is not possible to ascertain percentage of program expenditure reaching 
Aboriginal women 
 
• Grants to the states are untied. 
 
Practice Incentive Program (PIP) Cervical Screening Incentive 
 
• ACCHSs ‘locked out’ by PIP ineligibility, expenditure did not reach ACCHSs  
 
• Program poorly targeted to under-screened Aboriginal women 
 
• Evaluation findings withheld from the public  
 
• For example (information was obtained through Senate Estimates): 
o In 2004–05, there were only 279 claims under the cervical prevention PIP 
from Aboriginal medical services across Australia 
o Claims from 33 services totalled $9765 or $296 each 
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o Services reaching the screening target numbered 16 with payment of $1666 
each. 
 
MBS rebates for Pap smears 
 
• Rebates not accessible to AHWs 
 
• AHWs are important in taking Pap smears 
 
• AHWs outnumber practice nurses 2:1 and 90% of nurses are non-Indigenous 
(within ACCHSs). 
 
Aboriginal women 
 
• Mainstream policies don’t always work for the Aboriginal population, that’s why 
government supports supplementary population programs for this population 
(NSFATSIH) 
 
• Increased access to both core primary health care and supplementary population 
programs are needed to reduce cervical cancer 
 
• Any ‘cost-effectiveness-driven’ reductions in cervical cancer screening (now that 
we have HPV vaccine) should not apply to the population of Aboriginal women 
(there is an underspend for their health care) 
 
Making existing policies relevant 
 
• There are number of ways to make existing cancer prevention policies more 
relevant to this population:  
o Incentive programs must be designed to support Indigenous-specific 
service providers like ACCHSs instead of ‘locking them out’ 
o Include provider incentives for Pap smears from Aboriginal women 
o Introduce AHW MBS rebates 
o Public Health Outcomes Funding Agreements must require disaggregated 
Pap participation rates (for Aboriginal women) 
o Registers must include Aboriginal identifiers nationally 
o Establish PHOFA targets for Aboriginal women's Pap coverage 
o Implementation strategies needed for item 710 adult health check Medicare 
rebate; and for incentives MBS items targeted for ACCHSs 
o Promote case studies/exemplar sites for Pap coverage. 
 
Conclusion 
 
• HPV vaccine wont stop the need for Pap smears for Aboriginal women [in the 
short-term] because: 
o access to vaccine wont be optimal  
o vaccine won’t affect those already affected by HPV 
o we don’t know about non-vaccine-type HPV infections  
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• Pap smear coverage won’t improve unless Indigenous specific primary health care 
is enhanced and supplementary population programs for cervical cancer prevention 
are funded 
 
• Pap smear coverage won’t improve unless existing policies are made relevant to 
Aboriginal women and their service providers 
 
• Support ACCHSs to distribute HPV vaccine (eg. communication strategy for 
services and Aboriginal women) 
 
________________________________________________________________________ 
 
 
National HPV Vaccination Program: Information for parents, young women 
and immunisation providers 
 
 
- Andriana Koukari, Assistant Secretary, Targeted 
Prevention Programs Branch, Population Health 
Division, Department of Health and Ageing 
 
Background 
 
• Vaccination program announced 
29 November 2006 
 
• Eligible cohorts: 
o ongoing school program 
o school and community-based catch 
up program 
 
• To be implemented from April 2007, with 
materials in place by March 2007.  
 
Testing messages 
 
• HPV and the link to cervical cancer (and 
genital warts) 
 
• There is a vaccine available that prevents the HPV types that cause 70% of 
cervical cancer 
 
• HPV vaccine is most effective prior to commencement of sexual activity 
 
• Women will still need to have regular Pap smears – the vaccine doesn’t prevent all 
types of cervical cancer causing HPV types. 
 
Campaign development 
 
Formative research: 
 
• Conducted in January and February 2007 
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• Key findings: 
o Questioners/accepters 
o Knowledge deficit about HPV 
o Anxiety about ‘cancer’ 
o Concern about lack of information 
 
Target markets: 
 
• 14-17 year olds 
 
• 18-26 year olds 
 
• Parents  
 
• GPs. 
 
Campaign resources 
 
• Print advertisements 
 
• Pamphlets 
 
• Website – www.health.gov.au/cervicalcancer  
 
• Translated fact sheets 
 
• GP booklet 
 
• GP cheat sheet. 
 
Implementation 
 
Two phases in 2007 
 
• Phase 1: Mainstream target audiences 
o Print ads 
o Radio ads 
o Pamphlet 
o Website 
 
• Phase 2: People from culturally and linguistically diverse backgrounds and 
Aboriginal and Torres Strait Islander peoples 
 
Evaluation 
 
• Benchmark research has been conducted 
 
• Tracking research will be conducted over the next two years 
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• Communications/education strategy will be adjusted according to research findings 
 
________________________________________________________________________ 
 
 
National HPV Vaccination Program: Rolling out the vaccine program – impact 
on the National Cervical Screening Program 
 
- Andriana Koukari, Assistant Secretary, Targeted 
Prevention Programs Branch, Population Health 
Division, Department of Health and Ageing (This the 
second of two presentations by Ms Koukari) 
 
New HPV vaccination program 
 
Funding 
 
• Vaccine - $436 million 
 
• Support - $101 million 
o States and territories – service delivery 
o Communication campaign 
o Register. 
 
Eligible cohorts 
 
Ongoing 
 
• 12-13 year old girls (school based) 
 
Catch-up 
 
• 14-18 year old girls (school based) 
 
• 18-26 year olds (community based) 
 
 
Rollout schedule 
 
State Estimated rollout date Calendar Year 2007 Calendar Year 2008 
ACT From 30 April 2007 Years 7, 10, 11,12 Years 7, 9, 10 
NSW Metro from 17 May** Years 10, 11, 12 Years 7, 8, 9, 10 
NT* From 16 April 2007  Years 10, 11, 12 Years 7, 8, 9, 10 
Qld From 17 April 2007 Years 10, 11, 12 Years 8, 9, 10 
SA From 2 April 2007 Years 8 to 12 Year 8 
Tas From 11 April 2007 Years 7, 10, 11, 12 Years 7 ,9, 10 
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Vic From 16 April 2007 Years 7, 10, 11, 12 Years 7, 9, 10 
WA* From 1 May 2007 Years 10, 11, 12 Years 7, 8, 9, 10 
 
*In some (smaller) areas the whole school will be vaccinated  
** Country and remote schools may be earlier. 
 
Consultation and collaboration 
 
• Expert group to develop and review materials 
 
• Jurisdictional immunisation coordinators 
 
• State and territory cervical screening program managers 
 
• Building connections between immunisation and cervical screening. 
 
National HPV Vaccination Program register 
 
• Collecting data beyond 7 year olds 
 
• Establishing a register for now and the future 
 
• Ensuring capacity to link between HPV vaccine register and Pap test registers. 
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